COVIDH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Covidh Technologies Executes Non-Binding LoI For 100% Stake Of iSERA Biological
Feb 23 (Reuters) - Covidh Technologies Ltd COVI.BO:
EXECUTES NON-BINDING LOI FOR 100% STAKE OF ISERA BIOLOGICAL
Source text: ID:nBSEbNhr1P
Further company coverage: COVI.BO
(([email protected];;))
Feb 23 (Reuters) - Covidh Technologies Ltd COVI.BO:
EXECUTES NON-BINDING LOI FOR 100% STAKE OF ISERA BIOLOGICAL
Source text: ID:nBSEbNhr1P
Further company coverage: COVI.BO
(([email protected];;))
Events:
Rights
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does iSERA Lifesciences do?
Aptus Industries Limited, a Public Limited Company established in 1993, operates in agricultural software, construction, and infrastructure projects. Headquartered in Hyderabad, Andhra Pradesh.
Who are the competitors of iSERA Lifesciences?
iSERA Lifesciences major competitors are Globesecure Technlgy, B2B Software Tech., Cranes Software, Aris International, Adroit Infotech, Vedavaag Systems, Hiliks Technologies. Market Cap of iSERA Lifesciences is ₹56 Crs. While the median market cap of its peers are ₹55 Crs.
Is iSERA Lifesciences financially stable compared to its competitors?
iSERA Lifesciences seems to be less financially stable compared to its competitors. Altman Z score of iSERA Lifesciences is 0 and is ranked 5 out of its 8 competitors.
Does iSERA Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. iSERA Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has iSERA Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances
How strong is iSERA Lifesciences balance sheet?
iSERA Lifesciences balance sheet is weak and might have solvency issues
Is the profitablity of iSERA Lifesciences improving?
Yes, profit is increasing. The profit of iSERA Lifesciences is ₹0.14 Crs for Mar 2025, -₹0.1 Crs for Mar 2024 and -₹0.11 Crs for Mar 2023
Is the debt of iSERA Lifesciences increasing or decreasing?
Yes, The net debt of iSERA Lifesciences is increasing. Latest net debt of iSERA Lifesciences is ₹1.56 Crs as of Mar-25. This is greater than Mar-24 when it was ₹0.18 Crs.
Is iSERA Lifesciences stock expensive?
iSERA Lifesciences is not expensive. Latest PE of iSERA Lifesciences is 0, while 3 year average PE is 43.43. Also latest EV/EBITDA of iSERA Lifesciences is 0.0 while 3yr average is 18.38.
Has the share price of iSERA Lifesciences grown faster than its competition?
iSERA Lifesciences has given better returns compared to its competitors. iSERA Lifesciences has grown at ~12436.58% over the last 3yrs while peers have grown at a median rate of 8.32%
Is the promoter bullish about iSERA Lifesciences?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 58.63% and last quarter promoter holding is 3.57%.
Are mutual funds buying/selling iSERA Lifesciences?
There is Insufficient data to gauge this.
